Overview

A Study to Evaluate the Continuous Safety and Efficacy of BIIB059 in Adults With Active Systemic Lupus Erythematosus

Status:
Not yet recruiting
Trial end date:
2029-03-15
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the long-term safety and tolerability of BIIB059 in participants with active systemic lupus erythematosus (SLE). The secondary objectives of this study are to evaluate the long-term effect of BIIB059 on disease activity in participants with SLE, to evaluate the long-term effect of BIIB059 in participants with SLE in maintaining low disease activity, to evaluate the effect of BIIB059 in participants with active SLE in preventing irreversible organ damage, to assess long-term use of oral corticosteroid (OCS) with participants receiving BIIB059 treatment, to assess the impact of BIIB059 on participant-reported Health-Related Quality-of-Life Questionnaire (HRQoL), symptoms, and impacts of SLE, to evaluate long-term effect of BIIB059 on laboratory parameters, and to evaluate immunogenicity of BIIB059.
Phase:
Phase 3
Details
Lead Sponsor:
Biogen